Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis: Revenue Lags In Q1, Outlook Unchanged
03:18pm, Tuesday, 28'th Apr 2026
Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and
Novartis CEO warns of reality of Trump's drug pricing policy
01:04pm, Tuesday, 28'th Apr 2026
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
12:16pm, Tuesday, 28'th Apr 2026
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Tuesday, 28'th Apr 2026
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
Novartis shares fall after weak Q1 hit by Entresto competition
04:58am, Tuesday, 28'th Apr 2026
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugma
Novartis CEO: We knew these first two quarters would be bumpy
03:54am, Tuesday, 28'th Apr 2026
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
03:23am, Tuesday, 28'th Apr 2026
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
European markets to open higher as Trump considers Iran peace proposal
01:18am, Tuesday, 28'th Apr 2026
European stocks are expected to open higher on Tuesday as investors assess the latest developments in the Iran war, and look ahead to earnings reports.
Novartis Q1 profit down on US generic erosion
01:12am, Tuesday, 28'th Apr 2026
Swiss drugmaker Novartis reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
01:00am, Tuesday, 28'th Apr 2026
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc 1 , -1% USD), as growth drivers were more than offset by US generic erosion Continued strong performance from priori
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
01:20pm, Monday, 27'th Apr 2026
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
12:55pm, Monday, 27'th Apr 2026
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a
Novartis receives European Commission approval for Rhapsido skin disease drug
01:31am, Monday, 27'th Apr 2026
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
01:15am, Monday, 27'th Apr 2026
Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate respon
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
06:30am, Friday, 24'th Apr 2026
Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending m
